2024 HIV Prevention Drug Chart

[Jim Allen]

Pre-Exposure Prophylaxis (PrEP)

PrEP is antiretroviral medication taken by a person who is HIV negative to reduce the risk of contracting HIV.

There are currently three antiretroviral options approved by the Food and Drug Administration (FDA) for HIV prevention:

Truvada (tenofovir disoproxil fumarate/emtricitabine, or TDF/FTC)
Descovy (tenofovir alafenamide/emtricitabine, or TAF/FTC)
Apretude (long-acting cabotegravir)

Post-Exposure Prophylaxis (PEP)

PEP involves taking a short course of antiretroviral drugs, usually for a month, after a high-risk exposure to HIV. For maximum effectiveness, PEP should be started immediately—and no more than 72 hours—after possible exposure. The Centers for Disease Control and Prevention (CDC) recommends the following preferred HIV PEP regimen:

Isentress (raltegravir) - One tablet twice a day. Each tablet contains 400 mg of raltegravir. + Truvada (tenofovir disoproxil fumarate + emtricitabine)   
One tablet once a day. Each tablet contains 300 mg tenofovir disoproxil fumarate + 200 mg emtricitabine.

More information:
https://www.poz.com/article/2024-hiv-prevention-drug-chart
https://www.poz.com/basics/hiv-basics/pep-prep




Printable version of this drug chart:
https://www.poz.com/pdfs/POZ_2024_HIV_Prevention_Drug_Chart.pdf